Physician profile
Thomas Lee
NPI 1396122727
$1,833.19
in general payments reported to CMS, 2019-2025
12 companies · $17.05 in 2025
The $17.05 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.15 · 2020: $538 · 2021: $386 · 2022: $335 · 2023: $209 · 2024: $258 · 2025: $17.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $384 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $383.73 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $585.64 | 2020-2024 | |
| Janssen Biotech, INC. | $206.12 | 2022-2024 | Tremfya, Simponi Aria, Stelara |
| Genzyme Corporation | $194.38 | 2021-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $160.25 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $147.93 | 2021-2023 | Winlevi |
| Amgen INC. | $120.08 | 2023-2025 | Otezla, Enbrel, Otezla |
| Pfizer INC. | $72.74 | 2023 | |
| Lilly USA, LLC | $59.46 | 2021-2024 | Olumiant |
| Regeneron Healthcare Solutions, INC. | $42.30 | 2022-2024 | Libtayo |
| Stemline Therapeutics INC. | $20.05 | 2020 | |
| Arcutis Biotherapeutics, INC. | $19.01 | 2023 | |
| Kyowa Kirin, INC. | $15.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.